Batten Disease Treatment Market: Key Industry Trends, Growth Rate & With Forecast To 2026
Batten
disease is a rare, inherent, and fatal autosomal recessive neural
disorder that begins in the childhood but may take a few years to
show symptoms. Batten disease is one of the approximately 50 diseases
that fall under the category of lysosome shortage disorders. The
batten disease also referred as Neuronal ceroid Lipofuscinoses
(NCLs), which is a class of life-limiting genetic neurogenerative
diseases that are caused due to abnormality of genes resulting in
their inability to synthesize required protein. This disease is
characterized by malfunctioning of body, which usually appears around
the age of 2-10 with symptoms, such as seizures or gradual onset of
vision problem. The early signs may show subtle changes in behavior
and learning, however over time, the child suffers from mental
impairment, progressive loss of sight, speech and motor reactions,
worsening seizures, eventually leading to blindness dementia, and
finally death. These disease is diagnosed with the help of certain
tests, such as blood or urine tests, skin or tissue dampening, brain
scans, and imaging techniques, which includes, computed tomography
(CT) or magnetic resonance imaging (MRI). The batten disease is
characterized into four types as follows:
-
Infantile NCL: more than 2 years
-
Late Infantile NCL: 2-4 years (Life span of child varies between 8-12 years)
-
Juvenile NCL: 5-8 years (Life span varies between teens to early 20s)
-
Adult NCL: more than 40 years (Variable lifespan)
Request Sample
Copy of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/831
European
countries facing rising prevalence and incidence of batten disease
According
to the Centers for Disease Control and Prevention (CDC), Batten
disease is observed in 2-4 per 100,000 live births in the United
States on an average. The Batten disease although is rare but has
high incidence rates in Finland, Sweden, and other parts of the
Europe as compared to rest of the world. According to the Batten
Disease Support and Research Association, the batten disease has
often been encountered in more than one children of the same family.
The Daily News and Analysis article published in June 2016 suggests
that, over 20 million children in India suffer from rare diseases,
having expensive treatments. This creates opportunities for the
sustaining as well as upcoming market players by understanding the
potential held by the global batten disease treatment market.
The
global batten disease treatment market is segmented on the basis of
therapy and geographical regions.
On
the basis of therapy, the global batten disease treatment market is
segmented as
-
Occupational Therapies
-
Physical Therapies
Attempts
by collaborations of research bodies for introduction to reliable
treatment options for batten disease giving hopes to commoners
The
batten disease treatment market is not dense on the global level,
however the developed economies of North America and Europe are
expected to contribute to the growth of the market. This attributes
to the increasing incidence of batten disease and high prevalence
rates in American as well as European countries. For instance, a
joint study between Baylor College of Medicine, Texas Children’s
Hospital, and King’s College London have discovered a treatment
that has helped to improve the neurological symptoms in the mouse
model of juvenile batten disease. This research held a novel approach
of counteracting the accumulation of the cellular waste in Batten
disease by acting on TFEB, which is a master transcription factor
that stimulates the production of lysosomes by the cell body and
directs cellular apoptosis. This has brought a ray of hope to
patients and families affected by battens disease.
Improper
treatment facility for batten disease responsible to attract the
attention of various players to enter the untapped potential batten
disease treatment market
The
rising incidence of the batten disease without effective treatment
option for the prevention and cure of the disease is the primary
driver for batten disease market, due to which several companies are
vying to enter into the untapped global batten disease treatment
market. However, the lack of awareness among manufacturers and
patient population as well as unavailability of treatment for this
disease are greatly hampering the growth of the global batten disease
treatment market.
Although,
the global batten disease treatment market is very scarce, few key
players offering cell regeneration therapies and few other forms of
medication include Seneb BioSciences, Inc., BioMarin Pharmaceuticals
and ReGenX Biosciences LLC. The U.S. FDA has recently approved
BioMarin’s first ever drug to treat batten disease known as
Brineura in 2017.
Click
to read more on Batten
Disease Treatment Market
About
Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment